Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel

Basit Öğe Kaydı
dc.authoridSumbul, Ahmet Taner/0000-0002-5573-906X
dc.authoridsezer, ahmet/0000-0002-6445-1439
dc.authoridKose, Fatih/0000-0002-0156-5973
dc.authoridOzyilkan, Ozgur/0000-0001-8825-4918
dc.authoridMertsoylu, Huseyin/0000-0002-1932-9784
dc.contributor.authorSumbul, Ahmet Taner
dc.contributor.authorSezer, Ahmet
dc.contributor.authorAbali, Huseyin
dc.contributor.authorKose, Fatih
dc.contributor.authorGultepe, Ilhami
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorMuallaoglu, Sadik
dc.date.accessioned2024-09-18T20:08:04Z
dc.date.available2024-09-18T20:08:04Z
dc.date.issued2014
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractThe neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammatory response and evidences for the relationship between NLR and the response to treatment gradually increases in cancer patients. In this study, we aimed to investigate the effect of the pretreatment NLR and other factors related to the patient on predicting the outcome of docetaxel + prednisone chemotherapy in prostate cancer patients who become castration resistant. Thirty-three metastatic castration-resistant prostate cancer patients those who were treated between 2009 and 2013 were included in our study. All data of the patients, including pathological, clinical, radiological, biochemical and hematological data, were assessed retrospectively using our database system. The median progression-free survival (PFS) was determined as 23.9 months (range 0.36-118.7) with androgen suppression therapy and 9.5 months (range 1.7-39.4) with docetaxel + prednisone therapy. NLR was found to be correlated with only posttreatment psa levels. In the NLR a parts per thousand currency sign3 group, the PSA levels were statistically significantly lower than the other group (r = 0.002). Furthermore, the relationships between the clinical response and PFS and the other pretreatment parameters of the patients were evaluated in order to predict which group would respond better to docetaxel + prednisone therapy after becoming androgen resistant. No relationship was found between any of the parameters and the response to therapy. Although NLR was found effective in predicting the PSA response in docetaxel + prednisone therapy, neither NLR nor any other clinical parameter was found effective in predicting the outcome and the role of NLR in the future of CRPC is questionable.en_US
dc.identifier.doi10.1007/s11255-014-0664-7
dc.identifier.endpage1535en_US
dc.identifier.issn0301-1623
dc.identifier.issn1573-2584
dc.identifier.issue8en_US
dc.identifier.pmid24526335en_US
dc.identifier.scopus2-s2.0-84906938403en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1531en_US
dc.identifier.urihttps://doi.org/10.1007/s11255-014-0664-7
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8602
dc.identifier.volume46en_US
dc.identifier.wosWOS:000340523800010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Urology and Nephrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCastration-resistant prostate canceren_US
dc.subjectNeutrophil-to-lymphocyte ratioen_US
dc.subjectDocetaxel plus prednisoneen_US
dc.titleNeutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxelen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full text
Boyut:
229.5 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu